Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: A 10-year nationwide cohort study

Hepatology

Volumn 56, Issue 2, 2012, Pages 698-705

  Hsu, Yao Chun ^a,b   Lin, Jaw Town ^a,c,d   Chen, Tzu Ting ^e   Wu, Ming Shiang ^c   Wu, Chun Ying ^b,e,f,g  

^a I SHOU UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; PROPRANOLOL; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CRITICALLY ILL PATIENT; DEATH; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER BLEEDING; PORTAL HYPERTENSION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERTENSION, PORTAL; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORBIDITY; NATIONAL HEALTH PROGRAMS; PEPTIC ULCER HEMORRHAGE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 84864332234     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25684     Document Type: Article

References (38)

1. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. HEPATOLOGY 2003; 38: 599-612.
2. Lecleire S, Di Fiore F, Merle V, Herve S, Duhamel C, Rudelli A, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol 2005; 39: 321-327.
3. Hsu YC, Liou JM, Chung CS, Tseng CH, Lin TL, Chen CC, et al. Early risk stratification with simple clinical parameters for cirrhotic patients with acute upper gastrointestinal bleeding. Am J Emerg Med 2010; 28: 884-890.
4. Afessa B, Kubilis PS. Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 2000; 95: 484-489.
5. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832.
6. Weiler H, Weiler C, Gerok W. Gastric mucosal prostaglandin E2 levels in cirrhosis and portal hypertension. J Hepatol 1990; 11: 58-64.
7. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol 2002; 37: 463-470.
8. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. HEPATOLOGY 2006; 44: 1039-1046.
9. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46: 927-934.
10. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
11. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-321.
12. Guglielmi A, Ruzzenente A, Sandri M, Kind R, Lombardo F, Rodella L, et al. Risk assessment and prediction of rebleeding in bleeding gastroduodenal ulcer. Endoscopy 2002; 34: 778-786.
13. Marmo R, Koch M, Cipolletta L, Capurso L, Pera A, Bianco MA, et al. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study. Am J Gastroenterol 2008; 103: 1639-1647.
14. Wu CY, Wu CH, Wu MS, Wang CB, Cheng JS, Kuo KN, et al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009; 7: 427-431.
15. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-1648.
16. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010; 28: 2952-2957.
17. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut 2011; 60: 1038-1042.
18. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. HEPATOLOGY 2003; 37: 902-908.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980.
20. Marubini E, Valsecchi MG: Analysing Survival Data from Clinical Trials and Observational Studies. New York, NY: John Wiley and Sons; 1995.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
23. Siringo S, Burroughs AK, Bolondi L, Muia A, Di Febo G, Miglioli M, et al. Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol 1995; 22: 633-641.
24. Di Mario F, Gottardello L, Germana B, Dotto P, Grassi SA, Vianello F, et al. Peptic ulcer in cirrhotic patients: a short- and long-term study with antisecretory drugs. Ital J Gastroenterol 1992; 24: 122-125.
25. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89: 273-293.
26. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. HEPATOLOGY 2006; 43: S121-S131.
27. Calatayud S, Ramirez MC, Sanz MJ, Moreno L, Hernandez C, Bosch J, et al. Gastric mucosal resistance to acute injury in experimental portal hypertension. Br J Pharmacol 2001; 132: 309-317.
28. Tsugawa K, Jones MK, Akahoshi T, Moon WS, Maehara Y, Hashizume M, et al. Abnormal PTEN expression in portal hypertensive gastric mucosa: a key to impaired PI 3-kinase/Akt activation and delayed injury healing? FASEB J 2003; 17: 2316-2318.
29. Wu CS, Lin CY, Liaw YF. Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. Gastrointest Endosc 1995; 42: 424-427.
30. Chen LS, Lin HC, Hwang SJ, Lee FY, Hou MC, Lee SD. Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. J Gastroenterol Hepatol 1996; 11: 59-64.
31. Kitano S, Dolgor B. Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis? J Gastroenterol 2000; 35: 79-86.
32. Lo GH, Yu HC, Chan YC, Chen WC, Hsu PI, Lin CK, et al. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc 2005; 62: 350-356.
33. Hung LC, Ching JY, Sung JJ, To KF, Hui AJ, Wong VW, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845-1850.
34. Wong GL, Wong VW, Chan Y, Ching JY, Au K, Hui AJ, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009; 137: 525-531.
35. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008; 148: 258-267.
36. Van der Hulst RW, Rauws EA, Koycu B, Keller JJ, Bruno MJ, Tijssen JG, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-1086.
37. Tzathas C, Triantafyllou K, Mallas E, Triantafyllou G, Ladas SD. Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study. J Clin Gastroenterol 2008; 42: 744-749.
38. Savarino V, Mela GS, Zentilin P, Mansi C, Mele MR, Vigneri S, et al. Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. J Hepatol 1996; 25: 152-157.